luxabendazole: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 72019 |
| CHEMBL ID | 2104764 |
| SCHEMBL ID | 321908 |
| MeSH ID | M0162198 |
| Synonym |
|---|
| hoe 216v |
| methyl 5-hydroxy-2-benzimidazolecarbamate, p-fluorobenzenesulfonate (ester) |
| luxabendazolum [latin] |
| luxabendazol [spanish] |
| methyl 5-(4-fluorophenylsulfonyloxy)benzimidazole-2-carbamate |
| ccris 7645 |
| luxabendazole |
| 2-benzimidazolecarbamate, 5-hydroxy-, p-fluorobenzenesulfoonate |
| [2-(methoxycarbonylamino)-3h-benzimidazol-5-yl] 4-fluorobenzenesulfonate |
| 90509-02-7 |
| AKOS015967126 |
| luxabendazolum |
| unii-34s1s00gv3 |
| luxabendazole [inn:ban] |
| luxabendazol |
| 34s1s00gv3 , |
| AKOS015901189 |
| luxabendazole [inn] |
| CHEMBL2104764 |
| hoe-216v |
| SCHEMBL321908 |
| ZVIDWFUBDDXAJA-UHFFFAOYSA-N |
| DTXSID00238189 |
| luxabendazole, vetranal(tm), analytical standard |
| 2-((methoxycarbonyl)amino)-1h-benzo[d]imidazol-5-yl 4-fluorobenzenesulfonate |
| J-505262 |
| Q27256388 |
| benzenesulfonic acid, 4-fluoro-, 2-[(methoxycarbonyl)amino]-1h-benzimidazol-6-yl ester |
Luxabendazole is a new benzimidazole carbamate chemotherapeutic agent. It has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Luxabendazole is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. " | ( Bacterial mutagenic evaluation of Luxabendazole, a new broad spectrum anthelmintic, with the Salmonella typhimurium His- and the Escherichia coli Tryp- reversion tests. Barea, M; Ordóñez, D; Ortiz, AI; Pollastrini, MT, 1996) | 2.02 |
| "Luxabendazole (LBZ) is a new benzimidazole carbamate chemotherapeutic agent, which has proved to be very effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes. " | ( Pharmacokinetics of intravenous luxabendazole in rabbits: influence of the enterohepatic circulation. Alvarez-Bujidos, L; Cubría, C; Molina-Martínez, IT; Ordóñez, D; Ortiz, AI, 1998) | 2.03 |
Luxabendazole has a mean half-life of 8.5 years. Administration of the drug in sheep was slow.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Determination of pharmacokinetic parameters is the first step in determining a safe and efficacious dosage regimen for luxabendazole in sheep." | ( Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep. Alvarez-Bujidos, L; Ferre, I; Ordóñez, D; Ortiz, AI, 1997) | 0.83 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Mean bioavailability was 29%." | ( Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep. Alvarez-Bujidos, L; Ferre, I; Ordóñez, D; Ortiz, AI, 1997) | 0.62 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Determination of pharmacokinetic parameters is the first step in determining a safe and efficacious dosage regimen for luxabendazole in sheep." | ( Pharmacokinetics of luxabendazole after oral and intravenous administration to sheep. Alvarez-Bujidos, L; Ferre, I; Ordóñez, D; Ortiz, AI, 1997) | 0.83 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 7 (87.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||